These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 14523278)

  • 1. Case series of acute hepatitis in a non-selected group of HIV-infected patients on nevirapine-containing antiretroviral treatment.
    de Maat MM; ter Heine R; van Gorp EC; Mulder JW; Mairuhu AT; Beijnen JH
    AIDS; 2003 Oct; 17(15):2209-14. PubMed ID: 14523278
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy.
    Martínez E; Blanco JL; Arnaiz JA; Pérez-Cuevas JB; Mocroft A; Cruceta A; Marcos MA; Milinkovic A; García-Viejo MA; Mallolas J; Carné X; Phillips A; Gatell JM
    AIDS; 2001 Jul; 15(10):1261-8. PubMed ID: 11426070
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy.
    Lyons F; Hopkins S; Kelleher B; McGeary A; Sheehan G; Geoghegan J; Bergin C; Mulcahy FM; McCormick PA
    HIV Med; 2006 May; 7(4):255-60. PubMed ID: 16630038
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk and determinants of developing severe liver toxicity during therapy with nevirapine-and efavirenz-containing regimens in HIV-infected patients.
    Ena J; Amador C; Benito C; Fenoll V; Pasquau F
    Int J STD AIDS; 2003 Nov; 14(11):776-81. PubMed ID: 14624743
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence and risk factors for nevirapine-associated rash.
    de Maat MM; ter Heine R; Mulder JW; Meenhorst PL; Mairuhu AT; van Gorp EC; Huitema AD; Beijnen JH
    Eur J Clin Pharmacol; 2003 Sep; 59(5-6):457-62. PubMed ID: 12920493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and genetic factors associated with increased risk of severe liver toxicity in a monocentric cohort of HIV positive patients receiving nevirapine-based antiretroviral therapy.
    Giacomelli A; Riva A; Falvella FS; Oreni ML; Cattaneo D; Cheli S; Renisi G; Di Cristo V; Lupo A; Clementi E; Rusconi S; Galli M; Ridolfo AL
    BMC Infect Dis; 2018 Nov; 18(1):556. PubMed ID: 30419834
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence and risk factors of skin rashes and hepatotoxicity in HIV-infected patients receiving nevirapine-containing combination antiretroviral therapy in Taiwan.
    Tseng YT; Yang CJ; Chang SY; Lin SW; Tsai MS; Liu WC; Wu PY; Su YC; Luo YZ; Yang SP; Hung CC; Chang SC
    Int J Infect Dis; 2014 Dec; 29():12-7. PubMed ID: 25312984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and risk factors of nevirapine-associated severe hepatitis among HIV-infected patients with CD4 cell counts less than 250 cells/microL.
    Manosuthi W; Sungkanuparph S; Tansuphaswadikul S; Chottanapund S; Mankatitham W; Chimsuntorn S; Sittibusaya C; Moolasart V; Chaovavanich A
    J Med Assoc Thai; 2008 Feb; 91(2):159-65. PubMed ID: 18389979
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Liver toxicity caused by nevirapine.
    González de Requena D; Núñez M; Jiménez-Nácher I; Soriano V
    AIDS; 2002 Jan; 16(2):290-1. PubMed ID: 11807315
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nelfinavir and nevirapine side effects during pregnancy.
    Timmermans S; Tempelman C; Godfried MH; Nellen J; Dieleman J; Sprenger H; Schneider ME; de Wolf F; Boer K; van der Ende ME;
    AIDS; 2005 May; 19(8):795-9. PubMed ID: 15867493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatotoxicity following nevirapine-containing regimens in HIV-1-infected individuals.
    De Maat MM; Mathôt RA; Veldkamp AI; Huitma AD; Mulder JW; Meenhorst PL; Van Gorp EC; Carlier H; Beijnen JH
    Pharmacol Res; 2002 Sep; 46(3):295-300. PubMed ID: 12220974
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liver transplantation for fulminant hepatitis related to nevirapine therapy.
    Buyse S; Vibert E; Sebagh M; Antonini T; Ichai P; Castaing D; Samuel D; Duclos-Vallée JC
    Liver Transpl; 2006 Dec; 12(12):1880-2. PubMed ID: 17133571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hepatotoxicity associated with nevirapine or efavirenz-containing antiretroviral therapy: role of hepatitis C and B infections.
    Sulkowski MS; Thomas DL; Mehta SH; Chaisson RE; Moore RD
    Hepatology; 2002 Jan; 35(1):182-9. PubMed ID: 11786975
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Substitution of nevirapine or raltegravir for protease inhibitor vs. rosuvastatin treatment for the management of dyslipidaemia in HIV-infected patients on stable antiretroviral therapy (Nevrast study).
    Calza L; Magistrelli E; Colangeli V; Borderi M; Bussini L; Bon I; Re MC; Viale P
    Infect Dis (Lond); 2017 Oct; 49(10):737-747. PubMed ID: 28683645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety and efficacy of once-daily didanosine, tenofovir and nevirapine as a simplification antiretroviral approach.
    Negredo E; Moltó J; Muñoz-Moreno JA; Pedrol E; Ribera E; Viciana P; Galindos MJ; Miralles C; Burger D; Rodriguez Fumaz C; Puig J; Gel S; Rodríguez E; Videla S; Ruiz L; Clotet B
    Antivir Ther; 2004 Jun; 9(3):335-42. PubMed ID: 15259896
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: a randomised non-inferiority trial.
    Bonnet M; Bhatt N; Baudin E; Silva C; Michon C; Taburet AM; Ciaffi L; Sobry A; Bastos R; Nunes E; Rouzioux C; Jani I; Calmy A;
    Lancet Infect Dis; 2013 Apr; 13(4):303-12. PubMed ID: 23433590
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatotoxicity in patients co-infected with tuberculosis and HIV-1 while receiving non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and rifampicin-containing anti-tuberculosis regimen.
    Mankhatitham W; Lueangniyomkul A; Manosuthi W
    Southeast Asian J Trop Med Public Health; 2011 May; 42(3):651-8. PubMed ID: 21706943
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug rash with eosinophilia and systemic symptoms syndrome and renal toxicity with a nevirapine-containing regimen in a pregnant patient with human immunodeficiency virus.
    Knudtson E; Para M; Boswell H; Fan-Havard P
    Obstet Gynecol; 2003 May; 101(5 Pt 2):1094-7. PubMed ID: 12738113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of antiretroviral drugs on liver fibrosis in HIV-infected patients with chronic hepatitis C: harmful impact of nevirapine.
    Macías J; Castellano V; Merchante N; Palacios RB; Mira JA; Sáez C; García-García JA; Lozano F; Gómez-Mateos JM; Pineda JA
    AIDS; 2004 Mar; 18(5):767-74. PubMed ID: 15075511
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HBV, HCV, and HBV/HCV co-infection among HIV-positive patients in Hunan province, China: Regimen selection, hepatotoxicity, and antiretroviral therapy outcome.
    Su S; Fairley CK; Sasadeusz J; He J; Wei X; Zeng H; Jing J; Mao L; Chen X; Zhang L
    J Med Virol; 2018 Mar; 90(3):518-525. PubMed ID: 29091279
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.